Scorpius Holdings, Inc.
SCPX
Market cap $2.11M

0.6763 USD

-0.0637

8.61%

At close Nov 15, 4:00 PM EST

After hours

0.6500

-0.0263

3.89%

1 day

-8.61%

5 days

-24.86%

1 month

-9.83%

3 months

-28.81%

6 months

-95.65%

Year to date

-99.11%

1 year

-99.11%

5 years

-99.11%

10 years

-99.11%

About: Scorpius Holdings Inc is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities.

Employees: 84

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,704 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

22,787% more capital invested

Capital invested by funds: $1.95K [Q2] → $446K (+$444K) [Q3]

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

71% more funds holding

Funds holding: 7 [Q2] → 12 (+5) [Q3]

19.8% more ownership

Funds ownership: 0.05% [Q2] → 19.86% (+19.8%) [Q3]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for SCPX.

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about SCPX published over the past 30 days

Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability

DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today provided a strategic, financial, and operational update for the third quarter ended September 30, 2024.

Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability

Scorpius Holdings Announces Collaboration with Celltheon Corporation, a U.S.-Based Cell Line Development Company; First Client Signed Under New Partnership Agreement

DURHAM, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO"), today announced a partnership with Celltheon Corporation to provide cell line development services to clients using Celltheon's proprietary GOLDILOCKS™ transposase-based platform.

Scorpius Holdings Announces Collaboration with Celltheon Corporation, a U.S.-Based Cell Line Development Company; First Client Signed Under New Partnership Agreement

Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected to Save Over $2 Million Annually

DURHAM, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated biomanufacturing company, today announced the implementation of strategic cost-saving measures expected to save over $2 million annually.

Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected to Save Over $2 Million Annually

Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA

Collaboration Aims to Expedite the Development of Critical Solutions for Public Health Threats, Including Pandemic Preparedness and Emerging Infectious Diseases Collaboration Aims to Expedite the Development of Critical Solutions for Public Health Threats, Including Pandemic Preparedness and Emerging Infectious Diseases

Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA

Scorpius Holdings CEO Provides Corporate Update; Highlights Expanding Sales Pipeline, Enhanced Manufacturing Capabilities, and Path Toward Positive Cash Flow

DURHAM, N.C., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO"), today released a letter to shareholders from its CEO Jeff Wolf:

Scorpius Holdings CEO Provides Corporate Update; Highlights Expanding Sales Pipeline, Enhanced Manufacturing Capabilities, and Path Toward Positive Cash Flow

Scorpius Holdings Achieves 16% Year-Over-Year Increase in Revenue for the Second Quarter of 2024

Reduces operating expenses by 25% Pipeline surpasses $100 million in weighted opportunities across the government and manufacturing sectors DURHAM, N.C., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today provided strategic, financial, and operational updates for the second quarter ended June 30, 2024.

Scorpius Holdings Achieves 16% Year-Over-Year Increase in Revenue for the Second Quarter of 2024

Scorpius Holdings, Inc. Announces Closing of Public Offering

DURHAM, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius”, or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the closing of its underwritten public offering of 14,375,000 shares of common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof), including full exercise of the underwriter's over-allotment option. Each share of common stock (or Pre-Funded Warrant) was offered at a public offering price of $1.00 per share (inclusive of the Pre-Funded Warrant exercise price), for gross proceeds of $14,375,000, before deducting underwriting discounts and offering expenses.

Scorpius Holdings, Inc. Announces Closing of Public Offering

Scorpius Holdings, Inc. Announces Pricing of Public Offering

DURHAM, N.C., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius”, or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the new pricing of an underwritten public offering of 12,500,000 shares of common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof). Each share of common stock (or Pre-Funded Warrant) is being offered at a public offering price of $1.00 per share (inclusive of the Pre-Funded Warrant exercise price). The gross proceeds to the Company from the offering are expected to be approximately $12,500,000, before deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,875,000 shares of common stock and/or Pre-Funded Warrants solely to cover over-allotments, if any. As previously announced, the Company had terminated the pricing of its underwritten public offering that it had announced on August 6, 2024. Subsequently, the Company requested, and the NYSE American approved, a financial viability exception to the NYSE American stockholder approval rules that would allow the Company to proceed with the closing of the underwritten public offering upon the terms set forth above.

Scorpius Holdings, Inc. Announces Pricing of Public Offering

Scorpius Holdings, Inc. Provides Update on its Previously Announced Public Offering

DURHAM, N.C., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius”, or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced a delay in its previously announced public offering. The Company has requested, and the NYSE has approved, a financial viability exception to the NYSE American shareholder approval rules that would allow it to proceed with the closing of an underwritten public offering. The Company intends to pursue the sale of 12,500,000 shares of common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof, exclusive of the over-allotment option) at a price of $1.00 per share (inclusive of the Pre-Funded Warrant exercise price). The underwriting agreement was terminated in connection with the previously announced offering and a new underwriting agreement will be entered into if the offering is consummated. There can be no assurance that the Company will be able to consummate an offering under these terms or otherwise. The Company will adhere to all applicable provisions relating to the exemption, as outlined in Section 710 of the NYSE American Company Guide, and a closing is intended to occur ten days following the mailing of a notification letter to the Company's shareholders.

Scorpius Holdings, Inc. Provides Update on its Previously Announced Public Offering

Why Is Scorpius (SCPX) Stock Down 79% Today?

Scorpius (NYSEMKT: SCPX ) stock is taking a beating on Wednesday after the company provided details on a public offering. Scorpius has announced that it will sell 12.5 million shares of SCPX stock in this public offering.

Why Is Scorpius (SCPX) Stock Down 79% Today?

See News Rankings

Charts implemented using Lightweight Charts™